Skip to main content
Clinical Trials/KCT0005190
KCT0005190
Active, not recruiting
未知

Effectiveness of theraPeutic drug mOnitoring (TDM) on mucosal and transmural healing in pediatric patients with moderate to severe luminal CroHn’s disease newly receiving Remsima(infliximab): EPOCH study

Samsung Medical Center0 sites116 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the digestive system
Sponsor
Samsung Medical Center
Enrollment
116
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Pediatric patients aged 6–20 years with moderate to severe CD who requires infliximab.
  • \[Patients with Pediatric Crohn’s Disease Activity Index (PCDAI) \=30 in the European Crohn’s and Colitis Organisation and European Society of Pediatric Gastroenterology, Hepatology, and Nutrition guidelines.]
  • 2\) Pediatric patients without biologic agent administration in previous treatments.
  • 3\) Pediatric patients who do not show treatment response or tolerance to corticosteroids, immunomodulators, and primary nutritional therapy, or those for whom these treatments are contraindicated.
  • 4\) Pediatric patients whose legal guardians and who themselves provided consent to participation in this study.

Exclusion Criteria

  • 1\) Patients with mild CD
  • 2\) Patients aged less than 6 years, or 21 years or older
  • 3\) Patients with ulcerative colitis
  • 4\) Patients with a history of hypersensitivity to humanized protein
  • 5\) Patients who require infliximab treatment for anal fissure
  • 6\) Patients who are taking corticosteroids (Patients may be included if the steroid dosage is being tapered to halt steroid use.)
  • 7\) Patients with a previous history of tuberculosis
  • 8\) Patients who have had tuberculosis but have been confirmed to have undergone anti\-tuberculosis therapy for the minimum period required by a tuberculosis therapy guideline, and are willing to complete the therapy may be included.
  • 9\) Patients who visit a doctor for a medical check\-up, and have purified protein derivative (PPD) skin test or interferon\-? release assay (IGRA) results within the last 6 months may be included.
  • 10\) Patients with chronic type B hepatitis not receiving any treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials